炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征患者排卵的影响 点击下载
论文标题: 炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征患者排卵的影响
英文标题:
中文摘要:

目的:探讨炔雌醇环丙孕酮联合二甲双胍对多囊卵巢综合征(PCOS)患者排卵的影响。方法:184例PCOS患者随机分为对照组(92例)和观察组(92例)。对照组患者于月经开始第5天起口服炔雌醇环丙孕酮片1片,每日1次,连用21 d后停药,并于撤退性出血第5天起开始下一周期治疗,连续治疗3个月经周期。观察组患者在对照组治疗的基础上口服二甲双胍片3片,每日1次,月经期间不停药,连用3个月经周期。治疗3个月经周期后,两组患者均开始促排卵治疗[(第4个月经周期的月经开始第5天起,口服克罗米芬50~100 mg,连用5 d,或肌内注射人绝经后促性腺激素75~150 U,待优势卵泡直径为(19.0±2.0)mm时肌内注射人绒毛膜促性腺激素10 000 U,继续监测排卵情况,同时观察是否发生卵巢过度刺激综合征(OHSS)]。观察两组患者治疗前后的体质量指数(BMI)、卵泡刺激素(FSH)、黄体生成素(LH)、催乳素(PRL)、雌二醇(E2)、睾酮(T)、空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR),记录妊娠率、排卵率、OHSS发生率及不良反应发生情况。结果:治疗前,两组患者BMI、FSH、LH、PRL、E2、T、FPG、FINS、HOMA-IR比较,差异均无统计学意义(P>0.05)。治疗后,观察组患者BMI、LH、PRL、E2、T、FPG、FINS、HOMA-IR及对照组LH、E2、FINS均显著低于同组治疗前,且观察组BMI、PRL、E2、T、FPG、FINS、HOMA-IR低于对照组,差异均有统计学意义(P<0.05)。观察组患者排卵率、妊娠率均显著高于对照组, OHSS发生率显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 :炔雌醇环丙孕酮联合二甲双胍可有效改善POCS患者胰岛素抵抗的状态,恢复性激素分泌水平,有效促进排卵,提高妊娠率,且安全性较好。

 

英文摘要: OBJECTIVE: To discuss the effect of Ethinylestradiol and cyproterone acetate tablet combined with metformin on ovulation induction of patients with polycystic ovarian syndrome (PCOS). METHODS: 184 PCOS patients were randomly divided into control group (92 cases) and observation group (92 cases). Control group orally received 1 Ethinylestradiol and cyproterone acetate tablet in 5 d of menstruation, once a day, it stopped after 21 d, the next cycle of treatment was started on the 5th of withdrawal bleeding. Observation group additionally received 3 Metformin tablet, once a day, without drug withdrawal during menstruation, and lasted for 3 menstrual cycles. After 3 menstrual cycles, all patients received ovulation induction treatment [(50-100 mg clomiphene was orally given from the 5th day of the 4th menstrual cycle, for 5 days, or 75-150 U postmenopausal gonadotropin by intramuscular injection, when the dominant follicle diameter was (19.0±2.0)mm, 10 000 U human chorionic gonadotropin (HCG) was intramuscularly injected, the ovulation was continuously monitored and whether there was ovarian hyperstimulation syndrome (OHSS) was observed]. Body mass index (BMI), follicle estrogen (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2) and testosterone (T) before and after treatment, fasting plasma glucose (FPG), fasting insulin (FINS), insulin resistance index (HOMA-IR), pregnancy rate, ovulation rate and the incidences of OHSS and adverse reactions in 2 groups were observed.RESULTS: Before treatment, there were no significant differences in the BMI, FSH, LH, PRL, E2, T, FPG, FINS and HOMA-IR between 2 groups (P>0.05). After treatment, BMI, LH, PRL, E2, T, FPG, FINS and HOMA-IR in observation group and LH, E2 and FINS in control group were significantly lower than before, and BMI, PRL, E2, T, FPG, FINS and HOMA-IR in observation group were lower than control group, the differences were statistically significant (P<0.05). The pregnancy rate and ovulation rate in observation group was significantly higher than control group, the incidence of adverse reactions was significantly lower than control group, the differences were statistically significant (P<0.05). And there was no significant difference in the incidence of adverse reactions between 2 groups (P>0.05). CONCLUSIONS: Ethinylestradiol and cyproterone acetate combined with metformin can effectively improve insulin resistance of POCS patients, recovery sex hormone secretion, promote ovulation and improve pregnancy rate, with good safety.
期刊: 2016年第27卷第24期
作者: 徐岚,熊煜
英文作者: XU Lan,XIONG Yu
关键字: 炔雌醇环丙孕酮;二甲双胍;多囊卵巢综合征;促排卵
KEYWORDS: Ethinylestradiol and cyproterone acetate tablet; Metformin; Polycystic ovarian syndrome; Ovulation induction
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!